RecruitingPhase 2NCT06222723

LAssa Fever Adjunct Treatment With DEXamethasone

Safety and Tolerability of Adjunct Dexamethasone in Addition to Standard of Care Antiviral Therapy Compared to Standard of Care Antiviral Therapy Alone for the Treatment of Moderate to Severe Lassa Fever


Sponsor

Bernhard Nocht Institute for Tropical Medicine

Enrollment

42 participants

Start Date

Feb 5, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Dexamethasone is a corticosteroid which can modulate inflammatory-mediated tissue damage associated with a wide range of infectious diseases. Dexamethasone is routinely used for treatment of tuberculous meningitis and for pneumococcal meningitis in adults. In Coronavirus Disease 2019 (COVID-19) dexamethasone is also effectively preventing immune mediated damage of the lungs. There is also indication that dexamethasone may be promising in severe LF.


Eligibility

Min Age: 18 Years

Inclusion Criteria11

  • Age ≥ 18 years
  • LF confirmed by RT-PCR (reverse-transcription polymerase chain reaction) with a cycle threshold (Ct) value < 30
  • Signs of significant health impairment as evidenced by any of the following:
  • Alert, confusion, voice, pain, unresponsive (ACVPU) other than A
  • Systolic blood pressure < 90 mmHg
  • Seizure(s), meningism, coma, focal neurological deficit
  • AST (GOT) >3xULN
  • ALT (GPT) > 3xULN
  • KDIGO 2 or more severe based on serum creatinine only
  • Active macroscopic bleeding
  • O2 saturation < 92

Exclusion Criteria6

  • Pregnancy (evidenced by positive urine pregnancy test in women of child-bearing potential)
  • Lactation following live birth
  • Known intolerance and contra-indications to ribavirin or dexamethasone
  • Patients who already received a corticosteroid within the preceding 7 days
  • Investigator's valuation that patient might be put to substantial risk by participating in this trial
  • Patients receiving end-of-life care as judged by the investigator

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDexamethasone

Dexamethasone will be administered for 10 days. For the first 48 hours, dexamethasone will be given iv. After 48 hours, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.

DRUGRibavirin

Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.


Locations(1)

Irrua Specialist Teaching Hospital

Irrua, Edo, Nigeria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06222723


Related Trials